Keywords: angiotech, issues, guidance, 2004-6, canada, pharmaceuticals, issued
Angiotech issues guidance for 2004-6
Article | 05 July 2004
Canada's Angiotech Pharmaceuticals has issued revenue and earningsprospects for the years ending December 31, 2004, 2005 and 2006 at a meeting with analysts and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
